A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine
Purpose:Mutations in the fibroblast growth factor receptor 3 (FGFR3) occur in 50% of primary bladder tumors.An FGFR3 mutationis associatedwith goodprognosis, illustrated by significantly lower percentage of patients with progression and disease-specific mortality. FGFR3 mutations are especially prevalent in low grade/stage tumors, with pTa tumors harboring mutations in 85% of the cases.These tumors recur in 70% of patients. Efficient FGFR3 mutation detection for prognostic purposes and for detectionof recurrences inurine is animportant clinical issue. Inthis paper, we describe a simple assay for the simultaneous detection of nine different FGFR3 mutations. Experimental Design: The assay consists of one multiplex PCR, followed by extension of primers for each mutation with a labeled dideoxynucleotide.The extended primers are separated by capillary electrophoresis, and the identity of the incorporated nucleotide indicates the presence or absence of amutation. Results: The assay was found to be more sensitive than single-strand conformation polymorphism analysis.Mutations could still be detected with an input of only 1ng of genomic DNA and in a 20-fold excess of wild-type DNA. Moreover, in urine samples from patients with a mutant tumor, the sensitivity of mutation detectionwas 62%. Conclusions:We have developed a fast, easy to use assay for the simultaneous detection of FGFR3 mutations, which can be of assistance in clinical decision-making and as an alternative for the follow-up of patients by invasive cystoscopy for the detection of recurrences in urine.
|Persistent URL||dx.doi.org/10.1158/1078-0432.CCR-05-1045, hdl.handle.net/1765/10783|
van Oers, J.M.M., Lurkin, I., van Exsel, A.J.A., Nijsen, Y., van Rhijn, B.W.G., van der Aa, M.N.M., & Zwarthoff, E.C.. (2005). A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clinical Cancer Research, 11(21), 7743–7748. doi:10.1158/1078-0432.CCR-05-1045